Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources.

ABSTRACT: Omidubicel is a nicotinamide-expanded stem cell product derived from umbilical cord blood (UCB). In a phase 3 randomized trial for high-risk hematologic malignancies, omidubicel had faster neutrophil engraftment and fewer infectious complications than standard UCB transplantation. However, the clinical outcomes of omidubicel relative to other stem cell donor sources are yet to be determined. Clinical data for patients who underwent allogeneic hematopoietic cell transplantation (HCT) with omidubicel and standard UCB were taken from the phase 3 trial. The Center for International Blood and Marrow Transplant Research (CIBMTR) registry provided contemporaneous comparator cohorts of patients who met the trial eligibility criteria and who received allogeneic HCT from matched unrelated (MUD), mis

SUBMITTER: Lin C 

PROVIDER: S-EPMC12805917 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature